Eton Pharmaceuticals announced the initiation of a pilot clinical study for ET-700, an extended-release zinc acetate formulation for Wilson disease, with topline results expected in the second half of 2026.
Key takeaways
First patient dosed in pilot study for ET-700, a proprietary extended-release zinc acetate for Wilson disease.
Study compares ET-700 twice-daily dosing against GALZIN three-times-daily and placebo in 36 healthy volunteers.
Topline results expected in second half of 2026; positive results would lead to pivotal study in early 2027.
CEO Sean Brynjelsen stated ET-700 has potential to exceed $100 million in peak annual U.S. sales if approved.
Primary endpoint is change in hepatic copper uptake measured by 64 Cu PET imaging over a four-week treatment period.